256 related articles for article (PubMed ID: 28552625)
61. Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient care.
Ruderman EM
Am J Manag Care; 2002 Apr; 8(6 Suppl):S171-80. PubMed ID: 11990862
[TBL] [Abstract][Full Text] [Related]
62. Biological therapies in the spondyloarthritides--the current state.
Braun J; Sieper J
Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
[TBL] [Abstract][Full Text] [Related]
63. Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis.
Lin YC; Dalal D; Churton S; Brennan DM; Korman NJ; Kim ES; Husni ME
Arthritis Care Res (Hoboken); 2014 Jan; 66(1):97-103. PubMed ID: 23983044
[TBL] [Abstract][Full Text] [Related]
64. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
[TBL] [Abstract][Full Text] [Related]
65. Rheumatologists' recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients' joint symptoms.
Taylor SL; Petrie M; O'Rourke KS; Feldman SR
J Dermatolog Treat; 2009; 20(6):350-3. PubMed ID: 19878036
[TBL] [Abstract][Full Text] [Related]
66. Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?
Więsik-Szewczyk E; Kucharczyk A; Świerkocka K; Rutkowska E; Jahnz-Różyk K
Clin Rheumatol; 2017 Jul; 36(7):1677-1681. PubMed ID: 28488125
[TBL] [Abstract][Full Text] [Related]
67. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system.
Yang TS; Chi CC; Wang SH; Lin JC; Lin KM
Int J Rheum Dis; 2016 Oct; 19(10):1002-1009. PubMed ID: 26404916
[TBL] [Abstract][Full Text] [Related]
68. Analysis of pharmaceutical care in patients with psoriatic arthritis using statutory health insurance data.
Sondermann W; Ventzke J; Matusiewicz D; Körber A
J Dtsch Dermatol Ges; 2018 Mar; 16(3):285-294. PubMed ID: 29537175
[TBL] [Abstract][Full Text] [Related]
69. Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: A nationwide, population-based observational study in Taiwan.
Wang TS; Hsieh CF; Tsai TF
J Dermatol Sci; 2016 Dec; 84(3):340-345. PubMed ID: 27576765
[TBL] [Abstract][Full Text] [Related]
70. Psoriatic arthritis.
Umezawa Y
J Dermatol; 2021 Jun; 48(6):741-749. PubMed ID: 34060132
[TBL] [Abstract][Full Text] [Related]
71. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control.
Furst DE; Tran M; Sullivan E; Pike J; Piercy J; Herrera V; Palmer JB
Clin Rheumatol; 2017 Sep; 36(9):2045-2054. PubMed ID: 28238086
[TBL] [Abstract][Full Text] [Related]
72. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
73. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis.
Salvarani C; Olivieri I; Pipitone N; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M;
Clin Exp Rheumatol; 2006; 24(1):70-8. PubMed ID: 16539822
[TBL] [Abstract][Full Text] [Related]
74. Psoriatic Arthritis: Newer and Older Therapies.
Chao R; Kavanaugh A
Curr Rheumatol Rep; 2019 Dec; 21(12):75. PubMed ID: 31865449
[TBL] [Abstract][Full Text] [Related]
75. Management of psoriatic arthritis by dermatologists - a German nationwide survey.
König A; Hofmann M; Kaufmann R; Müller-Stahl J; Pinter A
J Dtsch Dermatol Ges; 2023 Nov; 21(11):1351-1357. PubMed ID: 37814389
[TBL] [Abstract][Full Text] [Related]
76. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study.
Giacomelli R; Gorla R; Trotta F; Tirri R; Grassi W; Bazzichi L; Galeazzi M; Matucci-Cerinic M; Scarpa R; Cantini F; Gerli R; Lapadula G; Sinigaglia L; Ferraccioli G; Olivieri I; Ruscitti P; Sarzi-Puttini P
Rheumatology (Oxford); 2015 May; 54(5):792-7. PubMed ID: 25288786
[TBL] [Abstract][Full Text] [Related]
77. Improving recognition of psoriatic arthritis.
Conaghan PG; Coates LC
Practitioner; 2009 Dec; 253(1724):15-8, 2-3. PubMed ID: 20120827
[TBL] [Abstract][Full Text] [Related]
78. Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials.
Combe B; Behrens F; McHugh N; Brock F; Kerkmann U; Kola B; Gallo G
J Rheumatol; 2016 Jun; 43(6):1063-7. PubMed ID: 27134249
[TBL] [Abstract][Full Text] [Related]
79. Psoriatic arthritis: current therapy and future directions.
Huynh D; Kavanaugh A
Expert Opin Pharmacother; 2013 Sep; 14(13):1755-64. PubMed ID: 23815157
[TBL] [Abstract][Full Text] [Related]
80. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
